Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 413-550-5 | CAS number: 142068-96-0 H112339
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Summary of repeat-dose data
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 50 mg/kg bw/day
- Study duration:
- subchronic
- Species:
- rat
Additional information
Two studies of repeat dose exposure were conducted to assess the effects of the substance over prolonged exposure. The results were as follows:
Sub-acute 28-day study.
There were no treatment-related deaths or toxicologically significant effects on clinical condition, or food consumption. There were no treatment-related effects on bodyweight during weeks 1 to 4 of treatment. However, during the recovery period, group mean bodyweight for animals from a l000mg/kg/day group was slightly, but not statistically significantly, lower than that of the concurrent controls. Slight reductions in mean haemoglobin, haematocrit and red cell count were noted for females at 1000 mg/kg/day at terminal and recovery kill. Mean plasma alanine transaminase and/or alkaline phosphatase activities were also reduced for males and/or females at 250 and/or 1000 mg/kg/day at terminal kill, only.
Higher group mean kidney weights were noted for males and/or females at 250 and/or 1000mg/kg/day at terminal kill and for females, only, from the 1000mg/kg/day group at recovery kill. Kidney weights for two males from the l000 mg/kg/day group were also higher at recovery kill. Higher group mean liver weights far males from the 1000 mg/kg/day group were also apparent at recovery kill, only increased hyaline droplet formation in the proximal tubules of the kidneys of all males at 1000mg/kg/day, and a dose-related degeneration of the proximal tubules of all females at 250 or 1000mg/kg/day, was noted at terminal kill. At recovery kill, proximal tubule degeneration, similar to that seen for females at l000 mg/kg/day at terminal kill, was present in males and females from the 1000 mg/kg/day group.
Other histopathological changes considered to be related to treatment included minimal or slight mononuclear cell infiltration of the periportal areas of the liver from animals receiving 1000 mg/kg/day, at both terminal and recovery kills.
Widespread pink/purple staining of tissues and colouration of plasma, urine and/or faeces was seen for animals receiving 250 and/or 1000mg/kg/day throughout the dosing and/or recovery periods and was considered to be due to the highly coloured nature of the test material and not due to any histopathological change.
The no-observable effect level following daily oral administration to male and female rats for 28 days, is 50mg/kg/day.
Sub-chronic 90-day study
The oral administration of the test compound led to dose-dependent signs of toxicity. Main target organ was the kidney. Toxicity was further characterized by hypoplastic anemia with corroborating histopathological findings in spleen and bone marrow. Furthermore, as a consequence of severe systemic toxicity, also liver, ovaries, adrenal cortex, and serous coats were affected. By contrast, the discoloration of urine, feces, and/or skin was related to the tinctorial properties of the test substance (dye-stuff), but does not represent a toxicologically relevant finding
The slight changes in kidney pathology and/or urinalysis of individual low dose females can be interpreted as remnants of transient tubular degeneration. The slight decrease in hematocrit in females of this dose level is assessed as being a mild adverse effect, only due to the lack of a histopathological correlate or other concomitant changes in red blood cells.
The no observed adverse effect level (NOAEL) under the conditions of this study was 50 mg/kg bw/day in males, but below 50 mg/kg bw/day in females
It is considered that the substance is unlikely to be inhaled and the physicochemical and toxicological properties suggest low potential for significant rate of absorption through the skin. Hence evaluation of exposure via these routes is not applicable, given the use category of the substance.
The following information is taken into account for any hazard / risk assessment:
Assessment of repeated dose exposure by oral route is discussed below.
Value used for CSA (route: oral):
NOEL: ≤ 50 mg/kg bw/day (subacute; rat)
NOAEL: 50 mg/kg bw/day (subacute; rat)
Repeated dose toxicity: via oral route - systemic effects (target organ) urogenital: kidneys
Justification for classification or non-classification
The above studies have both been ranked reliability 1 according to the Klimish et al system. This ranking was deemed appropriate because the studies were conducted to GLP an in compliance with agreed protocols. Sufficient dose ranges and numbers are detailed; hence it is appropriate for use based on reliability and animal welfare grounds. As the effects noted are at higher dose levels and a number are considered adaptive rather than toxicological, no classification is proposed.
The above results triggered no classification under the Dangerous Substance Directive (67/548/EEC) and the CLP Regulation (EC No 1272/2008). No classification for prolonged effects is therefore required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.